Furthermore, the potential applications of SGLT-2 inhibitors in other kidney disease subtypes, such as IgA nephropathy, ADPKD, FSGS, and lupus nephritis, further broaden their clinical applications. The gene discussed is SLC5A2; the disease is focal segmental glomerulosclerosis.